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Abstract
Background: Despite vancomycin use is a major risk factor for the emergence of vancomycin resistance, it is
frequently inappropriately prescribed, especially as empirical treatment. We evaluated the effect of an antimicrobial
stewardship intervention targeting for inappropriate continued empirical vancomycin use.
Methods: This was a quasi-experimental study comparing vancomycin use in a 6-month pre-intervention and 6-
month intervention period. If empirical vancomycin was continued for more than 96 h without documentation of
beta-lactam-resistant gram-positive microorganisms, it was considered inappropriate continued empirical
vancomycin use. The intervention consisted of the monitoring of appropriateness by a pharmacist and direct
discussion with the prescribing physicians by infectious disease specialists when empirical vancomycin was
continued inappropriately. An interrupted time series analysis was used to compare vancomycin use before and
during the intervention.
Results: Following implementation of the intervention, overall vancomycin consumption decreased by 14.6%, from
37.6 defined daily doses (DDDs)/1000 patient-days in the pre-intervention period to 32.1 DDDs/1000 patient-days in
the intervention period (P < 0.001). The inappropriate consumption of vancomycin also declined from 8.0 DDDs/
1000 patient-days to 5.8 DDDs/1000 patient-days (P = 0.009).
Conclusion: Interventions such as direct communication with prescribing physicians and infectious disease
clinicians can help reduce the inappropriate continued use of vancomycin.
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specialist
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Background
Vancomycin use is a major risk factor for acquisition of
vancomycin-resistant Enterococci (VRE) [1], and infectious
diseases caused by VRE are associated with increased mor-
tality and length of hospital stay [2]. Also, the use of un-
necessary vancomycin exposes patients to the risk of
nephrotoxicity [3]. In 1995 the Centers for Disease Control
and Prevention (CDC) established guideline for the appro-
priate use of vancomycin to reduce vancomycin resistance
[4]. Since that time, many clinical guidelines recommended
that empirically initiated vancomycin should be stopped,
even in immunocompromised hosts, such as those with
neutropenia, if there is no evidence of beta-lactam-resistant
gram-positive infection [5, 6]. Despite these guidelines, 20%
to 70% of vancomycin use is inappropriate [7–11].
In our institution, over the last 12 years, about 60% of S.
aureus infections were methicillin-resistant (MRSA), and
this proportion has not changed significantly [12], whereas
vancomycin consumption has increased more than twofold,
from 18 defined daily doses (DDDs) per 1000 patient-days
to 40.0 DDDs per 1000 patient-days [13]. Our previous
analysis showed that a quarter of total vancomycin use rep-
resented inappropriately continued empirical use [14]. We
have been executing an antibiotics stewardship program in-
cluding an educational program, a computer-assisted anti-
biotic prescribing program, antimicrobial formulary
restriction, and a prior-approval program. Our prior ap-
proval program is not very restrictive: physicians who are
going to prescribe vancomycin have to describe the indica-
tion on a vancomycin order form which is modified from
the indications for vancomycin use developed by the CDC
[4]. Prescribing physicians are recommended, but not
obliged to obtain prior approval by an infectious diseases
specialist. In March 2015, the Antimicrobial Control Team
of Seoul National University Hospital established an inter-
vention to improve the appropriateness of empirical vanco-
mycin use. The intervention consisted of monitoring of
appropriateness by a pharmacist and direct discussion be-
tween the prescribing physicians and infectious disease spe-
cialists when empirical vancomycin was continued
inappropriately beyond 96 h. We report the details of the




This quasi-experimental study was performed in Seoul Na-
tional University Hospital, a 1778-bed, university-affiliated
tertiary hospital in South Korea. The study was divided into
two 6-month periods with respect to the intervention tar-
geting inappropriate continued empirical vancomycin use,
which began on March 16th 2015. We defined a 6-month
pre-intervention period from July 14th 2014 to January
13th 2015, with the subsequent 2-month regarded as a
washout period. The intervention period was then defined
as the 6-month from the start of the intervention on March
16th 2015 to September 15th 2015. The institutional review
board of Seoul National University Hospital reviewed the
study protocol and provided study approval. It waived the
requirement for written consent (IRB registration number
1407–043-593).
The intervention
During the intervention period, the pharmacist of the Anti-
biotic Control Team reviewed the medical records of pa-
tients for whom parenteral vancomycin was prescribed
every day. If empirical vancomycin was continued beyond
96 h without documentation of beta-lactam-resistant gram-
positive microorganisms, the pharmacist informed an infec-
tious disease specialist of the Antibiotic Control Team that
empirical vancomycin was being prescribed inappropriately.
The infectious disease clinician then met with, or phoned,
the prescribing physician, and urged him/her to discontinue
the vancomycin. Direct communication with the relevant
physicians was intended to take place within 48 h of the
time when infectious disease clinician was informed of the
inappropriate continued empirical vancomycin use. The in-
fectious disease clinician left a medical record of the recom-
mendation to the prescribing physician and the pharmacist
of the Antibiotic Control Team later confirmed that vanco-
mycin had been discontinued.
Data collection and definitions
We retrospectively reviewed the medical records of pa-
tients who had been prescribed at least one dose of par-
enterally administered vancomycin during the study
period. We included only patients who were at least
18 years of age.
The primary outcomes of the study were the total
amount of vancomycin prescribed, the amount of in-
appropriate continued empirical vancomycin use, and
the total amount of vancomycin prescribed that consti-
tuted inappropriate continued empirical use. Inappropri-
ate continued empirical vancomycin was defined as in
our previous report [14]. Briefly, we considered vanco-
mycin prescribed before obtaining the culture results to
be empirical. When empirically prescribed vancomycin
treatment was continued beyond 96 h without docu-
mentation of beta-lactam-resistant gram-positive micro-
organisms in clinical specimens with significance, the
continuation was considered inappropriate, and the
amount used thereafter was considered inappropriately
used. Vancomycin was calculated as defined daily doses
(DDDs) per 1000 patient-days in accordance with World
Health Organization recommendations [15]. Prescrip-
tions for the same patient that were separated by 8 days
or more were considered independent.
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Statistical analysis
Descriptive results for continuous variables were expressed
as median values and interquartile ranges (IQRs). Clinical
characteristics were compared using the chi-square test
and the Matt-Whitney test for categorical and continuous
variables, respectively. An interrupted time series analysis
was used to compare the amount of vancomycin use before
and after the intervention. Data analyses were performed
using SAS software (version 9.4; SAS Institute, Cary, North
Carolina).
Results
Vancomycin consumption in the pre-intervention period
During the pre-intervention period, a total of 1450
prescriptions of parenterally administered vancomycin
were provided for 1249 patients, corresponding to 37.
6 DDDs/1000 patient-days. Of the 1450 prescriptions,
212 (14.6%) were for specific treatment of docu-
mented infections, 347 (23.9%) were prophylactic, and
891 (61.5%) were empirical. The amounts consumed
for specific treatment, prophylaxis, and empirical
treatment were 8.5 DDDs/1000 patient-days (22.5%),
5.2 DDDs/1000 patient-days (13.8%), and 23.9 DDDs/
1000 patient-days (63.7%) respectively.
Intervention activity
During the intervention period, a total of 1457 pre-
scriptions of parenterally administered vancomycin
were given to 1244 patients. Of the 1457 prescrip-
tions, 908 (62.3%) were given empirically and 272
(18.7%) were continued inappropriately beyond 96 h
and became candidates for the intervention. An
infectious disease specialist intervened about 223
(82.0%) of these 272 prescriptions; 148 prescriptions
(66.4%, of 223 prescriptions) were discontinued within
24 h of the intervention, but 75 (33.6%) were continued.
Vancomycin consumption in the intervention period
During the intervention period, overall vancomycin
consumption decreased by 14.6%, from 37.6 DDDs/
1000 patient-days in the pre-intervention period to
32.1 DDDs/1000 patient-days in the intervention
period (P < 0.001, Fig. 1). In the latter period the
amounts consumed for specific treatment, prophylaxis, and
empirical treatment were 6.5 DDDs/1000 patient-days (20.
2%), 5.7 DDDs/1000 patient-days (17.8%), and 19.9 DDDs/
1000 patient-days (62.0%) respectively. During the interven-
tion period, the consumption for empirical use also was de-
clined significantly (P = 0.005, Table 1). The incidence of
MRSA bloodstream infection was 0.112 per 1000 patient-
days in the pre-intervention period and 0.147 per 1000
patient-days in the intervention period, with no significant
difference between the two periods (P = 0.272).
Inappropriate continued empirical vancomycin use
We identified 575 patients for whom empirical vanco-
mycin was continued inappropriately during this
study: 303 in the pre-intervention period and 272 in
the intervention period. The proportion of patients
with hematologic malignancies among the patients in
whom empirical vancomycin was continued inappro-
priately was significantly higher during the interven-
tion period, but the other baseline and clinical
characteristics of the two sets of patients did not differ
Fig. 1 Vancomycin consumption and appropriateness in the pre-intervention and intervention periods
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significantly (Table 2). In the pre-intervention period,
the amount of inappropriate continued empirical
vancomycin use was 8.0 DDDs/1000 patient-days,
representing 21.2% of the total parenterally adminis-
tered vancomycin. In the intervention period, the
inappropriate consumption of vancomycin declined to
5.8 DDDs/1000 patient-days (P = 0.009, Fig. 1). The pro-
portion of vancomycin consumption amount that was con-
tinued inappropriately also decreased, but not significantly
(21.2% to 18.1%, P = 0.087).
Table 1 The usage of vancomycin in the pre-intervention and intervention periods
Pre-intervention period Intervention period P value
Total amount of vancomycin prescribed (DDDs/1000 patient-days) 37.6 32.1 < 0.001
Amount of empirical vancomycin (DDDs/1000 patient-days) 23.9 19.9 0.005
Amount of inappropriate continued empirical vancomycin (DDDs/1000 patient-days) 8.0 5.8 0.009
Abbreviations: DDD defined daily dose
Table 2 Characteristics of patients in whom empirical vancomycin was continued inappropriately during the pre-intervention and
intervention periodsa
Pre-intervention period Intervention period P value
No. of prescriptions 303 272
Male, n (%) 181 (59.7) 163 (59.9) 0.963
Age, median years (IQR) 60 (48–71) 61 (49–72) 0.528
Comorbid condition, n (%)
Diabetes mellitus 68 (22.4) 53 (19.5) 0.385
Chronic liver disease 28 (9.2) 27 (9.9) 0.780
Chronic lung disease 10 (3.3) 1 (0.4) 0.010
Cerebrovascular disease 10 (3.3) 11 (4.0) 0.635
Solid malignancy 86 (28.4) 68 (25.0) 0.360
Hematological malignancy 58 (19.1) 72 (26.5) 0.036
Connective tissue disease 8 (2.6) 8 (2.9) 0.827
Azotemia 46 (15.2) 46 (16.9) 0.572
Neutropenia 61 (20.1) 63 (23.2) 0.378
Suspected site of infection, n (%) 0.214
Pneumonia 68 (22.4) 50 (18.4)
Intraabdominal infection 32 (10.6) 42 (15.4)
CNS infection 34 (11.2) 32 (11.8)
Skin and soft tissue infection 62 (20.5) 50 (18.4)
Cardiovascular infection 2 (0.7) 5 (1.8)
Catheter-related infection 25 (8.3) 16 (5.9)
Bone and joint infection 31 (10.2) 8 (2.9)
Urinary tract infection 5 (1.7) 3 (1.1)
Other infection 19 (6.3) 19 (7.0)
Unknown 25 (8.3) 47 (17.3)
Admission department, n (%) 0.303
Medial ward 165 (54.5) 176 (64.7)
Surgical ward 86 (28.4) 46 (16.9)
Medical ICU 33 (10.9) 30 (11.0)
Surgical ICU 19 (6.3) 20 (7.4)
30-days mortality, n (%) 53 (17.5) 37 (13.6) 0.200
Abbreviations: CNS central nervous system, ICU intensive care unit
aWhen empirically prescribed vancomycin treatment was continued beyond 96 h without documentation of beta-lactam-resistant gram-positive microorganisms
in clinical specimens with significance, the continuation was considered inappropriate
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Discussion
We have shown above that an intervention involving dir-
ect discussion between prescribing physicians and infec-
tious disease clinicians increased the appropriateness of
empirical vancomycin use. The intervention reduced the
amount of inappropriate continued empirical vanco-
mycin use from 8.0 to 5.8 DDDs/1000 patient-days, and
the total amount of vancomycin prescribed represented
by inappropriate continued empirical vancomycin use
fell from 21.2% to 18.1%.
There have been several investigations of the effects of
various interventions aimed at improving vancomycin use,
including pharmacists’ interventions, automatic stop or-
ders, antibiotic order forms, continuing education,
computer-assisted antibiotic prescribing programs, anti-
microbial formulary restrictions, and prior-approval pro-
grams. The effectiveness of pharmacists’ interventions was
demonstrated in a previous study [16]; the initial interven-
tions were performed by pharmacists, and if inappropriate
vancomycin use continued, a consultation with an infec-
tious disease clinician was offered. As a result, the accord
with guidelines for empiric use of vancomycin improved
from 47% in the pre-intervention period to 73% during
the intervention [16]. Another pharmacists’ intervention
consisting of contacting physicians and informing them of
inappropriate vancomycin use significantly improved ap-
propriate initiation of vancomycin [17]. These studies
demonstrated that direct interventions of pharmacist and
infectious disease clinicians with prescribers could be ef-
fective. An intervention consisting automatic 72 h stop or-
ders also improved vancomycin prescribing [18]. However
Bolon et al. reported that an antibiotic order form inter-
vention did not improve or reduce vancomycin use [19],
and the educational programs about vancomycin use
failed to reduce inappropriate vancomycin prescribing in a
prospective study [20].
An educational program, a computer-assisted antibiotic
prescribing program, and a prior approval program have
all been introduced in our institution to promote the pru-
dent use of broad-spectrum antibiotics including vanco-
mycin. Nevertheless, much of the vancomycin prescribed
has been used inappropriately. In our opinion education
and antibiotic order forms alone have little impact on the
appropriateness of antibiotic use, and more intensive in-
terventions such as direct discussions and compulsory
stop orders would be more helpful for antimicrobial stew-
ardship. Of course, such direct discussions with prescrib-
ing physician may not be long lasting, as it increases the
demands on the time of infectious disease clinicians.
Therefore, with this interventions, it is essential to estab-
lish local guidelines and policies for empirical prescribing.
In Korea, to promote appropriate use of antibiotics, the
Korea Centers for Disease Control and Prevention
(KCDC) is carrying out a Policy Research Serving Project
with related expert groups such as the Korean Society of
Infectious Diseases, Korean Society for Chemotherapy
since 2016 [21, 22].
Factors associated with the inappropriate use of vanco-
mycin, such as critical clinical conditions, absence of docu-
mented causative organism, and suspected CNS infection,
were identified in previous studies [7, 14]. In this study, pa-
tients with hematologic malignancies accounted for a sig-
nificantly higher proportion of the patients in whom
empirical vancomycin was continued inappropriately dur-
ing the intervention period than during the pre-
intervention period. This suggests that physicians treating
patients with hematologic malignancies tend to be less
compliant with intervention instructions.
Our study has several limitations. First, we only focused
on reducing the amount of inappropriate continued em-
pirical vancomycin use. Further interventions focused on
prophylaxis, specific treatments, and the initial choice of
empirical vancomycin would also be helpful in reducing
the total amount of vancomycin prescribed. Second, this
was a non-randomized, pre/post-intervention study and
the lack of random assignment weakens its significance.
Third, we did not investigate why many prescribers con-
tinued with inappropriate empirical vancomycin use after
discussion with infectious diseases clinicians.
Conclusions
Interventions such as direct communication with pre-
scribing physicians and infectious disease clinicians can
help reduce the inappropriate continued use of
vancomycin.
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